Search / Trial NCT00002414

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Launched by CENTAUR PHARMACEUTICALS · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Unknown status

Keywords

Aids Dementia Complex Anti Hiv Agents

ClinConnect Summary

Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Patients are randomized to receive either placebo or one of two oral doses of CPI-1189 daily. Patients are assessed for safety and tolerability during Weeks 2, 6, and 10. At Week 10, efficacy assessments are also made. For those who volunteer, a sample of cerebrospinal fluid is obtained at baseline and at Week 10. Blood samples for CPI-1189 pharmacokinetic trough measurements are taken at Weeks 2 and 10. The...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • Are HIV-positive.
  • Are at least 18 years old.
  • Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control.
  • Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs).
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • Have certain serious medical conditions, such as a mental disorder or an opportunistic (AIDS-related) infection.

Trial Officials

Clifford DB

Study Chair

About Centaur Pharmaceuticals

Centaur Pharmaceuticals is a leading biopharmaceutical company dedicated to advancing innovative therapies for unmet medical needs. With a strong focus on research and development, Centaur Pharmaceuticals leverages cutting-edge science and technology to create effective treatments across a range of therapeutic areas. Committed to the highest standards of clinical excellence, the company collaborates with healthcare professionals and regulatory bodies to ensure the safety and efficacy of its products. Through rigorous clinical trials and a patient-centered approach, Centaur Pharmaceuticals aims to improve patient outcomes and enhance the quality of life for individuals affected by various diseases.

Locations

San Diego, California, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

Saint Louis, Missouri, United States

New York, New York, United States

Rochester, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials